mRNA Vaccines Beyond COVID — The Platform That's Now Targeting Cancer and HIV

You've heard of mRNA vaccines because of COVID-19. But the technology itself is older than the pandemic by several decades, and the real story of where it's going has almost nothing to do with coronaviruses.

The basic idea behind mRNA vaccines is deceptively simple: instead of injecting a weakened pathogen or a protein fragment to train the immune system, you inject instructions. A short strand of messenger RNA, wrapped in a lipid nanoparticle shell, enters cells and directs them to produce a specific protein. The immune system recognizes that protein as foreign, mounts a response, and creates immunological memory. When the real pathogen shows up later displaying that same protein, the immune system already knows what to do.

## Why the 1980s Work Took Until 2021 to Arrive at a Pharmacy

The foundational science behind mRNA vaccines goes back to researchers at the University of Pennsylvania in the late 1980s and 1990s — most prominently Katalin Karikó and Drew Weissman. Their central problem was that synthetic mRNA triggered a violent immune response before it could even deliver its payload. The immune system treated the foreign RNA like an infection and destroyed it before any protein was made.

Karikó and Weissman's key insight, for which they received the Nobel Prize in Physiology or Medicine in 2023, was to substitute a modified nucleoside called pseudouridine into the mRNA sequence. This modification allowed synthetic mRNA to evade the innate immune sensors that would otherwise destroy it, while still directing protein production normally. It was a small chemical tweak with enormous consequences.

*Here's the weird part:* this discovery was made in 2005. The paper sat relatively undercited for years. Karikó, working against skepticism from academic grant committees who didn't see mRNA as a viable therapeutic platform, was actually demoted at Penn during this period. BioNTech and Moderna were among the small companies that recognized the potential and licensed the technology. When SARS-CoV-2 emerged in late 2019, those companies had a decade of development behind them. The pandemic didn't create mRNA vaccines — it finally gave them the emergency authorization pathway to reach the public.

## How the Lipid Nanoparticle Problem Was Solved

Even with stable, immunologically tolerated mRNA, there remained the delivery problem. mRNA is a fragile molecule that degrades rapidly in biological fluids. It can't just be injected into muscle — it would be broken down before entering cells. The solution is the *lipid nanoparticle* (LNP): a tiny fat bubble, roughly 100 nanometers in diameter, that encapsulates the mRNA and fuses with cell membranes to deliver the cargo directly into the cytoplasm.

Developing effective LNP formulations took years of optimization. The early formulations required ultra-cold storage (-70°C for the Pfizer-BioNTech vaccine) because the lipid shell was unstable at higher temperatures. More recent formulations have achieved refrigerator stability at 2-8°C, and research into thermostable mRNA is targeting room-temperature stability — which would be transformative for vaccine distribution in low-income countries without reliable cold chain infrastructure.

> 🔬 **Quick experiment:** The reason mRNA vaccines need cold storage isn't just about the RNA — it's primarily about the lipid nanoparticle shell. At elevated temperatures, the lipids rearrange and the particles aggregate, losing their ability to fuse with cell membranes efficiently.

## BioNTech's Cancer Vaccine: Personalized Medicine at Scale

The application that mRNA vaccine pioneers always considered the real prize was cancer. And it's now entering Phase 3 clinical trials.

Here's the fundamental insight: tumors are genetically unique. Each patient's cancer cells carry a distinct set of mutations — some shared across many patients, some entirely individual. These tumor-specific mutations produce altered proteins called *neoantigens* that the immune system should be able to recognize as foreign. The problem is that cancers evolve multiple immune escape mechanisms, and by the time a tumor is large enough to diagnose, the immune system has often been partially suppressed or tolerized.

The mRNA approach: sequence the patient's tumor DNA, run computational analysis to identify which mutations are most likely to produce neoantigens that the immune system can actually respond to, synthesize a personalized mRNA vaccine encoding roughly 20 of those neoantigens, and inject it to train the immune system to attack cells carrying those mutations.

BioNTech's mRNA-4157/V940, developed in partnership with Merck, completed Phase 2b trials in 2023 showing a 44% reduction in recurrence or death in melanoma patients when combined with Keytruda (pembrolizumab), an existing checkpoint inhibitor immunotherapy. Phase 3 trials began in 2024 across multiple cancer types — melanoma, non-small cell lung cancer, colorectal cancer, and others. Manufacturing turnaround time from tumor biopsy to finished vaccine is approximately six weeks.

## Moderna's HIV Approach: The Problem No Vaccine Has Solved

HIV has resisted vaccine development for forty years. The virus mutates so rapidly and targets the CD4+ T cells that are central to the immune response itself — the very cells that vaccines need to activate. Previous vaccine approaches failed because the immune system cannot generate broadly neutralizing antibodies against HIV through conventional exposure; it requires a specific, step-by-step germline education that ordinary vaccines can't provide.

Moderna's mRNA-1644, in clinical trials since 2022, takes a different approach. Rather than trying to generate protection against a single HIV strain, it uses a sequence of mRNA immunizations to guide B cells through a process called *germline targeting* — educating the immune system's antibody-producing machinery to follow a specific developmental pathway that ends with broadly neutralizing antibody production. Each successive immunization pushes the B cells one step further along the intended developmental trajectory.

Early Phase 1 data showed that the approach successfully induced the desired early B cell responses in a subset of participants — a proof of concept that the germline targeting strategy works in humans. Full broadly neutralizing antibody production would require additional booster immunizations over an extended period, but the mechanism is now validated.

## Why This Platform May Outpace CRISPR for Near-Term Impact

CRISPR gets more press, and its long-term potential for genetic disease is extraordinary. But mRNA's near-term therapeutic value is broader and more immediately actionable. mRNA doesn't edit the genome — it leaves no permanent trace, carries no off-target editing risk, and can be updated rapidly when a target protein changes (as happened with COVID-19 variant-specific boosters).

The platform is modular: the delivery system (LNP), manufacturing infrastructure, and regulatory framework built for COVID-19 vaccines can be redirected toward any protein target. The speed advantage is real — a new mRNA vaccine can go from target identification to clinical trial faster than any previous vaccine technology.

For cancer, the personalized mRNA approach represents something genuinely new: a therapeutic that is designed around each individual patient's tumor biology rather than a one-size-fits-all antigen. The question is no longer whether it can work — Phase 2 data suggests it can — but how broadly it can work, in which cancer types, at what cost, and at what scale.

## What We Still Don't Know

The open questions are substantial. Personalized cancer vaccines are expensive and complex to manufacture at scale; making them accessible outside wealthy healthcare systems will require cost reduction that hasn't happened yet. The optimal combination with other immunotherapies (checkpoint inhibitors, CAR-T) is still being worked out. Durability of response — how long the immune memory lasts — remains incompletely characterized across different cancer types.

And for HIV, the germline-targeting approach is theoretically elegant but practically unproven at the level that matters: actual HIV prevention in a real-world trial population. The immune system is not a straightforward machine, and what works in a controlled trial environment doesn't always translate to population-level protection.

But the direction is clear. The mRNA platform is not a one-pandemic wonder. It is a general-purpose biological programming language for the immune system, and COVID-19 was only the first sentence.

mRNA Vaccines Beyond COVID — The Platform That's Now Targeting Cancer and HIV

// COMMENTS

ON THIS PAGE